[Tiger’s Weekly Intel] – S&N and DePuy’s breakup over the corner office, PE’s efficiency bet, and BONESUPPORT’s margin model

The theme of last week was strategic consolidation, the hard truth about corporate governance, and the relentless flow of private capital toward operational efficiency over raw novelty. The biggest orthopedic deal of the year collapsed not over valuation, but over the corner office. Meanwhile, Stryker fought a robot war on one front while S&N's strategic options narrowed, BONESUPPORT posted a masterclass in orthobiologics margins, and private equity aggressively funded the software and manufacturing backbone of ambulatory surgery.

Sector Breakdown • LARGE-CAP / SPIN WATCH Notable Move: Smith & Nephew / J&J merger talks collapse over CEO selection; S&N faces Cevian (14.2%) pressure Key Implication: Clean exit for DePuy Synthes is off the table; J&J returns to Plan A spin by mid-2027 while S&N faces activist scrutiny. • ROBOTICS & ASCS Notable Move: RIVANNA scores 510(k) for BoneEnhance; TJO secures $11M credit facility for ASC expansion Key Implication: Capital favors point-of-care efficiency, tray reduction, and ASC inventory models over novel standalone implants. • ORTHOBIOLOGICS Notable Move: BONESUPPORT Q3 net sales +39% (SEK 408.8M); gross margin hi...


Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !
 

Scroll to Top